Related Experiment Video
Updated: May 7, 2026
07:34
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
[Patient with TDS and increased PSA (implications in prostate biopsy)]
1Servicio de Urologia. Hospital Clinico . Universidad de Barcelona.Barcelona.Spain.
Archivos Espanoles De Urologia
|September 20, 2013
Summary
Testosterone supplementation is not definitively linked to prostate cancer risk in men with hypogonadism. Current evidence suggests it may be safe, despite historical concerns regarding testosterone and prostate health.
Area of Science:
- Andrology
- Urology
- Endocrinology
Background:
- Testosterone's historical association with prostate cancer risk has led to caution regarding supplementation in hypogonadal men.
- Testosterone deficiency syndrome (hypogonadism) affects many men, necessitating careful consideration of treatment risks and benefits.
Observation:
- A case study of a man with hypogonadism and elevated prostate-specific antigen (PSA) is presented.
- The study details biopsy indications, risks of testosterone supplementation, and follow-up protocols.
Findings:
- The current evidence on the safety of testosterone supplementation for the prostate in hypogonadal men is reviewed.
- Analysis focuses on whether testosterone therapy increases the risk of developing prostate cancer.
Implications:
- This review provides a practical basis for understanding the current evidence on testosterone supplementation and prostate safety.
- Findings aim to guide clinical decisions regarding testosterone therapy in men with hypogonadism and elevated PSA.
